EUVIMEDEUVIMED entdecken
Open Access

Predicting targeted therapy resistance in non-small cell lung cancer using multimodal machine learning

Peiying Hua, Andrea Olofson, Faraz Farhadi, Liesbeth Hondelink, Gregory Tsongalis, Konstantin Dragnev, Dagmar Hoegemann Savellano, Arief Suriawinata, Laura Tafe, Saeed Hassanpour iD

Journal of Thoracic Disease · 2025-10 · 17 (10) · 8700-8714

DOI: 10.21037/jtd-2025-1012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thoracic Disease, 2025-10. Verfasst von Peiying Hua und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, NH, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NLM NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Resistance to tyrosine kinase inhibitors remains a major clinical challenge in the treatment of non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. Despite the efficacy of third-generation EGFR inhibitors, no standard tool currently exists to predict resistance using routinely available clinical data. In this study, we aim to develop a multimodal machine learning model to predict resistance in NSCLC patients using readily accessible clinical information.

Methods

We conducted a multi-institutional retrospective study to develop and evaluate a multimodal machine learning model for predicting therapy resistance in late-stage NSCLC patients with EGFR mutations. The study included 42 patients treated with EGFR-targeted therapy from Dartmouth-Hitchcock Medical Center and Ochsner Health System, using data including histology whole-slide images, next-generation sequencing results, and demographic and clinical variables. The modeling framework fused image and non-image data through a three-stage training process and was evaluated using 5-fold nested cross-validation. Model performance was assessed using the concordance index (C-index), Kaplan-Meier survival curves, and log-rank tests. Interpretability analyses were conducted using attention maps, feature importance coefficients, and cellular composition comparisons.

Results

The multimodal model achieved a mean C-index of 0.82 across cross-validation folds, outperforming image-only and non-image models (C-index 0.75 and 0.77, respectively). Stratified analyses across institutions confirmed consistent performance gains with the multimodal approach. Kaplan-Meier analysis revealed that the multimodal model significantly stratified patients into distinct hazard groups (log-rank P=0.04), which unimodal models failed to achieve. Key predictors included RB1 mutation and Hispanic ethnicity. Attention maps highlighted histologic regions with deformed nuclei, and cellular analysis revealed reduced inflammatory cell presence in high-risk patients.

Conclusions

This study presents a robust multimodal machine learning model for predicting therapy resistance in EGFR-mutant NSCLC, leveraging routinely collected clinical data without manual feature engineering. The model demonstrated superior performance over unimodal models and effective hazard stratification, suggesting utility for personalized treatment decisions. These findings underscore the potential of multimodal artificial intelligence (AI) tools to advance precision oncology, particularly in resource-limited settings. Further validation in larger, diverse cohorts is warranted.

Schlagwörter

Stichwörter der Autor:innen

Non-small cell lung cancer (NSCLC)multimodal machine learningprecision oncologytherapy resistance predictionwhole slide imaging

Autor:innen und Institutionen

  • Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
  • Department of Pathology, Ochsner Health System, New Orleans, LA, USA.
  • Department of Radiology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
  • Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
  • Department of Medical Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.

ORCID-Profile: Saeed Hassanpour

Förderung

  • NCI NIH HHS
  • NLM NIH HHS

Zitieren

APA

Hua, P., Olofson, A., Farhadi, F., Hondelink, L., Tsongalis, G., Dragnev, K., Hoegemann Savellano, D., Suriawinata, A., Tafe, L., & Hassanpour, S. (2025). Predicting targeted therapy resistance in non-small cell lung cancer using multimodal machine learning. Journal of Thoracic Disease, 17(10), 8700-8714. https://doi.org/10.21037/jtd-2025-1012

Vancouver

Hua P, Olofson A, Farhadi F, Hondelink L, Tsongalis G, Dragnev K, et al. Predicting targeted therapy resistance in non-small cell lung cancer using multimodal machine learning. Journal of Thoracic Disease. 2025;17(10):8700-8714. doi:10.21037/jtd-2025-1012

BibTeX
@article{Hua2025,
  author = {Hua, Peiying and Olofson, Andrea and Farhadi, Faraz and Hondelink, Liesbeth and Tsongalis, Gregory and Dragnev, Konstantin and Hoegemann Savellano, Dagmar and Suriawinata, Arief and Tafe, Laura and Hassanpour, Saeed},
  title = {Predicting targeted therapy resistance in non-small cell lung cancer using multimodal machine learning},
  journal = {Journal of Thoracic Disease},
  year = {2025},
  volume = {17},
  number = {10},
  pages = {8700--8714},
  doi = {10.21037/jtd-2025-1012}
}
Kostenlos starten →